100-0-3

Careinoma, infrittrating duct, NCS 8500/3 12/8/10 Jur Site Code: breast, NOS C50.9

UUID:8C7442C0-540C-4023-BBFA-8482935259A7 TCGA-E2-A15P-01A-PR **Re**

TSS:

SPECIMENS:

- A. RIGHT BREAST NEEDLE LOCALIZATION
- B. SENTINEL LYMPH NODE #1 RIGHT AXILLA
- C. SENTINEL LYMPH NODE #2 RIGHT AXILLA

SPECIMEN(S):

- A. RIGHT BREAST NEEDLE LOCALIZATION
- B. SENTINEL LYMPH NODE #1 RIGHT AXILLA
- C. SENTINEL LYMPH NODE #2 RIGHT AXILLA

INTRAOPERATIVE CONSULTATION DIAGNOSIS:

A- right breast: 1.5-cm mass at 0.5 cm from posterior margin.

TPB/TPC- SLN #1, #2 right axilla: Negative for tumor.

..(A) and Diagnoses called by Dr. to Dr. at 1

GROSS DESCRIPTION:

A. RIGHT BREAST NEEDLE LOC

Received fresh labeled with the patient's identification and "right breast needle loc" is a previously inked, oriented (single stitch-anterior, double-lateral, triple-anterior) 31 g, 3.5 x 3.1 x 3.1 cm needle localized lumpectomy with radiograph. Ink code: Anterior-yellow, posterior-black, medial-green, lateral-red, superior-blue, inferior-orange. Specimen is serially sectioned from superior to inferior into 8 slices revealing a 1.5 x 1.3 x 1.1 cm firm tan stellate mass that is closest to the posterior margin at 0.5 cm. Tissue is procured. Representatively submitted:

.(B, C).

A1: superior margin, perpendicular sections

A2: slice 2, posterior medial

A3: slice 3, anterior medial

A4: slice 4, posterior lateral

A5: slice 5, anterior lateral (mass, clip)

A6: slice 5, posterior lateral (mass)

A7: slice 5, mid anterior

A8: slice 5, mid posterior

A9: slice 5, medial

A10: slice 6, anterior lateral (mass)

A11: slice 6, posterior lateral

A12: slice 7, anterior lateral

A13: slice 7, posterior lateral

A14: slice 7, anterior medial

A15: slice 7, posterior medial

A16: inferior margin, perpendicular sections

B. SENTINEL LYMPH NODE #1 RIGHT AXILLA

Received fresh labeled with the patient's identification and "sentinel lymph node #1" is a 2 x 1 x 0.8 cm lymph node. Sectioned, touch preps are performed; lymph node is submitted entirely in cassette B1.

C. SENTINEL LYMPH NODE #2 RIGHT AXILLA

Received fresh labeled with the patient's identification and "sentinel lymph node #2" is a 1 x 0.8 x 0.5 cm lymph node. Sectioned, touch preps are performed; lymph node is submitted entirely in cassette C1.

DIAGNOSIS:

A. BREAST, RIGHT, WIDE LOCAL EXCISION:

- INVASIVE DUCTAL CARCINOMA, SBR GRADE 2, MEASURING 1.1-CM
- INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID TYPE
- SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR
- FIBROADENOMA (0.2-CM)
- BIOPSY SITE CHANGES WITH FIBROSIS AND FOREIGN BODY GIANT CELL REACTION
- SEE SYNOPTIC REPORT.

B. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION:

- ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1).

C. LYMPH NODE, SENTINEL #2, RIGHT AXILLA, EXCISION:

- ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1).

SYNOPTIC REPORT - BREAST

Specimen Type: Excision Needle Localization: Yes

Laterality: Right

Invasive Tumor: Absent

Multifocality: No

WHO CLASSIFICATION

Invasive ductal carcinoma, NOS 8500/3

Tumor size: 1.1cm Margins: Negative

Distance from closest margin: 0.5cm

deep

Tubular Score: 3 Nuclear Grade: Mitotic Score: 1

Modified Scarff Bloom Richardson Grade:

Necrosis: Absent

Vascular/Lymphatic Invasion: None identified

Lobular neoplasia: None Lymph nodes: Sentinel lymph node Lymph node status: Negative 0 / 2

DCIS present

Margins uninvolved by DCIS DCIS Quantity: Estimate 10%

DCIS Type: Solid

DCIS Location: Associated with invasive tumor

Nuclear grade: Intermediate Necrosis: Absent

ER/PR/HER2 Results

ER: Pending PR: Pending

HER2: Negative by IHC Performed on Case:

Pathological staging (pTN):

pT 1cN0 Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition

CLINICAL HISTORY:

Right lateral breast 1.5-cm invasive breast cancer, posterior near fascia, fascia included with specimen.

PRE-OPERATIVE DIAGNOSIS:

None given

ADDENDUM:

SYNOPTIC REPORT - BREAST, ER/PR RESULTS

Specimen: Surgical Excision

Block Number: A6

ER: Positive Allred Score: 8 = Proportion Score 5 + Intensity Score 3 PR: Positive Allred Score: 4 = Proportion Score 2 + Intensity Score 2

COMMENT:

The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring range from 0 to 8.

ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score of less than or equal to 2.

METHODOLOGY:

Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR 136, 1:100) following the manufacturer s instructions. This assay was not modified. provided by Dakc Interpretation of the ER/PR immunohistocnemical stain is guided by published results in the medical literature, information provided by the reagent manufacturer and by internal review of staining performance.

ONCOTYPE DX BREAST CANCER ASSAY

RESULTS: Recurrence Score:

CLINICAL EXPERIENCE: Patients with a recurrence score of: 22 in the clinical validation study had an average rate of Distant Recurrence at 10 years of 14%



ER Score:

11.1 Positive 4.4 Negative

PR Score: Her2 Score: 10 Negative

Interpretation:

Negative < 6.5 Positive >= 6.5 ER

PR Negative < 5.5 Positive >= 5.5
Her2 Negative <10.7 Positive >= 11.5 Equivocal = 10.7 - 11.4

See separate (

report for further information.

Test performed at:

Microscopic/Diagnostic Dictation: Pathologist, Final Review: Pathologist,

Final: Pathologist, Addendum: Pathologist, Addendum Final: Pathologist. Addendum: Pathologist, Addendum Final: Pathologist,

Criterio
Diagnosis Discrepancy
Primary Tumor Site Ciscrepancy
-IIPAA Discrepancy
-IIIPAA DISCR